Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica plc has granted nil-cost share options to its top executives under the 2024 Long Term Incentive Plan, with the performance conditions based on EBITDA margin and revenue growth. The grants, which are adjusted based on a percentage of the grantees’ salaries, will vest in 2027 subject to the achievement of set targets. The move aligns with the company’s growth strategy and incentivizes its leadership team to drive financial success.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
